L. Hanson

发表

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

P. LoRusso, J. Sebolt-Leopold, A. Adjei, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer

Sumithra J. Mandrekar, J. Jett, S. Mandrekar, 2007, Clinical Cancer Research.

A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer

S. Mandrekar, A. Adjei, G. Dy, 2005, Cancer Chemotherapy and Pharmacology.

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer

S. Mandrekar, G. Wilding, S. Alberts, 2005, Clinical Cancer Research.

APhase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor , PS-341 ( Bortezomib , Velcade ) , in Patientswith Advanced Cancer

S. Alberts, H. Pitot, C. Erlichman, 2005 .

Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.

J. Sloan, R. Diasio, R. Goldberg, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer

S. Mandrekar, H. Pitot, C. Erlichman, 2005, Clinical Cancer Research.

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

J. Sloan, R. Marks, R. Goldberg, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

J. Sloan, R. Goldberg, S. Alberts, 2005, Cancer Chemotherapy and Pharmacology.

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies

S. Mandrekar, S. Alberts, H. Pitot, 2006, Cancer Chemotherapy and Pharmacology.

A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)

J. Jett, S. Mandrekar, R. Marks, 2005 .

A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM).

H. Wakelee, B. Sikic, A. Adjei, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

Mojun Zhu, A. Tan, A. Adjei, 2020, Investigational New Drugs.

Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.

J. Jett, J. Sloan, R. Goldberg, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complementary and alternative medicine use by patients enrolled onto phase I clinical trials.

J. Sloan, S. Mandrekar, A. Adjei, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

W. R. Bishop, J. Sloan, J. Sloan, 2000, Cancer research.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

W. Franklin, L. Chow, S. Leong, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.

R. Marks, E. Vokes, C. Erlichman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.

J. Sloan, R. Goldberg, S. Alberts, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

J. Sloan, R. Goldberg, S. Alberts, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

History of the development of antiemetic guidelines at Mayo Clinic Rochester.

P. Southorn, D. Farley, C. Loprinzi, 2000, Mayo Clinic proceedings.

A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer

J. Sloan, R. Goldberg, S. Alberts, 2002, Investigational New Drugs.

A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients.

S. Mandrekar, A. Adjei, C. Erlichman, 2004, Journal of Clinical Oncology.

A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies

H. Wakelee, B. Sikic, A. Adjei, 2005 .

A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors

S. Mandrekar, R. Marks, A. Adjei, 2005 .

Complementary and alternative medicine (CAM) use by patients enrolled in phase I clinical trials

J. Sloan, S. Mandrekar, A. Adjei, 2004 .

Phase I I S tudy o f t he F arnesyl T ransferase I nhibitor R 115777 in P atients W ith A dvanced N on-Small-Cell L ung C ancer

R. Marks, E. Vokes, C. Erlichman, 2003 .

A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM).

B. Sikic, A. Adjei, J. Reid, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.